BIOCYTOGEN

Biocytogen is a clinical stage biopharmaceutical company that integrates proprietary gene editing technology, transgenic mouse platforms to generate fully human antibodies, comprehensive animal models and high-throughput in vivo antibody discovery. We have established fully integrated research and development capabilities ranging from early target discovery to clinical development. Our focus on research and development and technological innovation serves as the cornerstone of our continuing growth. We intend to develop and commercialize first-in-class or best-in-class drugs to contribute to the improvement of human health worldwide.

#SimilarOrganizations #People #Financial #More

BIOCYTOGEN

Social Links:

Linkedin

Facebook

X

Youtube

Industry:

Biotechnology Health Care Medical Device Therapeutics

Founded:

2008-11-01

Status:

Active

Contact:

781-587-3558

Email Addresses:

[email protected]

Total Funding:

335.15 M USD

Technology used in webpage:

Domain Not Resolving IPv6 Person Schema Google Google Cloud Cloudflare Hosting Facebook Sharer Gravatar Profiles SiteXpress

Similar Organizations

symap-medical-logo

SyMap Medical

SyMap Medical is an innovative medical device company.

Current Employees Featured

yuelei-shen_image

Yuelei Shen
Yuelei Shen President & CEO @ Biocytogen
President & CEO
2008-06-01

not_available_image

Tianquan Jin
Tianquan Jin Vice President @ Biocytogen
Vice President
2011-11-01

chaoshe-guo_image

Chaoshe Guo
Chaoshe Guo Vice President Sales and Marketing @ Biocytogen
Vice President Sales and Marketing
2016-04-01

Founder

yuelei-shen_image

Yuelei Shen

Stock Details

Company's stock symbol is HKG:02315

Investors List

remegen_image

Remegen

Remegen investment in Post-IPO Equity - Biocytogen

veken-technology_image

Veken Technology

Veken Technology investment in Post-IPO Equity - Biocytogen

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series E - Biocytogen

citic-pe_image

CPE

CPE investment in Series E - Biocytogen

octagon-capital-partners_image

Octagon Capital Partners

Octagon Capital Partners investment in Series E - Biocytogen

lake-bleu-capital_image

Lake Bleu Capital

Lake Bleu Capital investment in Series E - Biocytogen

cmbi-international-capital-corporation_image

CMB International Capital Corporation

CMB International Capital Corporation investment in Series D - Biocytogen

china-life-healthcare-fund_image

China Life Healthcare Fund

China Life Healthcare Fund investment in Series D - Biocytogen

cowin-capital_image

Cowin Capital

Cowin Capital investment in Series D - Biocytogen

3e-bioventures_image

3E Bioventures

3E Bioventures investment in Series D - Biocytogen

Investments List

Date	Company	Article	Money raised
2022-06-02	Doma Biopharmaceutical	Biocytogen investment in Series A - Doma Biopharmaceutical	950 M CNY

More informations about "Biocytogen" on Search Engine